Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia

@article{Hornberger2012CosteffectivenessOA,
  title={Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia},
  author={John C. Hornberger and Carolina M. Reyes and Ashwini Shewade and Susan Lerner and Mark Friedmann and Leona C. Han and Hialy R. Gutierrez and Sacha Satram-Hoang and Michael J. Keating},
  journal={Leukemia \& Lymphoma},
  year={2012},
  volume={53},
  pages={225 - 234}
}
Abstract A recent phase III trial demonstrated improved progression-free survival (PFS) and overall survival (OS) associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was performed from a US third-party payer perspective over a lifetime horizon in the base case. One-way, two-way and probabilistic sensitivity analyses were conducted to… 
View on Taylor & Francis
cedarecon.com
25 Citations
Highly Influential Citations
3
Background Citations
9
Methods Citations
3
Results Citations
3

25 Citations

Citation Type

Citation Type

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
TLDR
The aim of this study was to assess the cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide scheme (FCR versus FC) for treatment-naïve and refractory/relapsed Ukrainian patients with chronic lymphocytic leukemia.
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia
TLDR
From the German SHI perspective, rituximab in combination with FC chemotherapy represents good value for first-line treatment of patients with CLL and compares favorably with chemotherapy alone.
Cost-effectiveness Analysis of Rituximab Associated With Fludarabine and Cyclophosphamide (R-FC) for the First-line Treatment of Chronic Lymphocytic Leukemia Under the Brazilian Public Health System (SUS).
TLDR
From the Brazilian public health system perspective, the combination of rituximab with the FC chemotherapy represents a cost-effective strategic approach for first-line treatment of patients with CLL.
Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse
TLDR
Rituximab, in combination with chemotherapy, when used multiple times throughout the treatment algorithm, appears to be cost effective for CLL from the Australian healthcare perspective, with a cost/QALYG within the range generally accepted as providing value.
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
TLDR
Using GClb to treat patients with previously untreated CLL for whom full-dose fludarabine-based therapy is unsuitable allows significant gains in terms of LYs and QALYs versus treatment with RClb, and can be regarded as efficient when considered the willingness to pay thresholds commonly used in Spain.
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
Economic Evaluation of Ibrutinib as First-Line Treatment of Unfit Patients with Chronic Lymphocytic Leukemia in the Netherlands and the Potential Role of Precision Medicine
TLDR
Ibrutinib for previously untreated and unfit CLL patients in the Netherlands is not a cost-effective strategy compared to the standard treatment of GClb when an €80,000 ICER threshold is used.
Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
TLDR
The sequential application of TKIs is standard-of-care, and thus, the analysis points toward imatinib followed by nilotinib as the most cost-effective strategy.
Decitabine is more cost effective than cytarabine and daunorubicin in elderly acute myeloid leukemia patients
TLDR
Decitabine is a more cost-effective therapy for patients older than 60 years of age than AD and may be arguably considered for elderly newly diagnosed AML patients given the economic pressures in the US health system; however, this is not a criterion for drug approval.
...
1
2
3
...

References

SHOWING 1-10 OF 97 REFERENCES
Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
TLDR
The addition of rituximab to cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma increases median time to progression by 17 months and the cost-effectiveness ratio of R-CVP compared with CVP is projected to be cost-effective in the United States under a range of sensitivity analyses.
Treatment Effect of First Line Rituximab, Fludarabine and Cyclosphosphamide in a Chronic Lymphocytic Leukemia Patient Cohort: An Evaluation of Prognostic Factors, Estimated Life Expectancy and Economic Outcomes
TLDR
The treatment benefit of R- FC over FC in this CLL observational cohort is not affected by prognostic factors, and R-FC patients experienced longer PFS which translated into a considerable increase in life expectancy at an acceptable cost to the US healthcare system.
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
TLDR
In a multivariate analysis of patients receiving fludarabine-based therapy at the center, FCR therapy emerged as the strongest independent determinant of survival.
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
  • T. Robak, A. Dmoszyńska, +17 authors S. Moiseev
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
PURPOSE Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered…
Update in the management of chronic lymphocytic leukemia
TLDR
There remains a need for more effective therapies in both the upfront and relapsed setting, particularly for patients with high-risk cytogenetic abnormalities such as del(11q22) and del(17p13), and a multi-center study suggested that the high CR rates to chemoimmunotherapy regimens such as FCR obtained in academic centers may not be reproducible when the same regimens are given in the community setting.
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
TLDR
The combination of etanercept and thrice weekly rituximab produces durable remissions in non-del(17p13.1) CLL patients and is well tolerated.
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
TLDR
The clinical response of fludarabine-refractory CLL patients treated with high-dose methylprednisolone (HDMP) and rituximab and the overall survival and time-to-progression were superior to those of other published salvage regimens.
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
  • J. Byrd, T. Murphy, +11 authors I. Flinn
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
TLDR
Initial infusion-related events seem to be cytokine mediated and resolve by the third infusion making rapid administration possible, and future combination studies of rituximab with other therapies in CLL seem warranted.
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century.
TLDR
Long-term survival expectations of patients with CLL have substantially improved over the past 2 decades except for patients 80 years of age or older at the time of diagnosis, and increases in 5- and 10-year absolute and relative survival over time were rather homogeneous across age groups.
...
1
2
3
4
5
...